Digital Service Expansion Cyprotex's launch of the e-Store platform for online ordering of ADME-Tox services indicates a strategic focus on expanding digital accessibility, providing a seamless channel for acquiring in vitro and in silico testing services which can be leveraged to upsell automated workflows or new testing modules.
Innovative Service Offerings The company's recent addition of transcriptomics and GIANTmicrobes mitochondria testing demonstrates a commitment to diversifying its service portfolio, creating opportunities to cross-sell advanced toxicology and genomics solutions to current and prospective clients seeking comprehensive data sets.
Strategic Acquisitions Cyprotex's acquisitions, including Searchonamerica and Apredica, suggest a growth strategy that can be capitalized on by offering integrated research services, as well as targeted solutions for clients interested in expanding their early discovery and toxicology capabilities.
Global Presence and Leadership With sites in the UK and USA and being part of the Evotec group, Cyprotex holds a strong geographical presence and industry backing, which provides opportunities to target multinational pharmaceutical and biotech firms looking for reliable, scalable ADME-Tox and R&D support.
Growth and Revenue Potential Operating within a competitive landscape with a revenue range of 10 to 50 million and recent financing, Cyprotex's demonstrated capacity for innovation and expansion signals ongoing growth opportunities to clients investing in cutting-edge, customizable early-stage research services.
$10M$25M
$500M$1B
$100M$250M
$250M$500M
$25M$50M
$1M
$50M$100MCyprotex uses 8 technology products and services including Cookiebot, ISO/IEC 27001, Indeed, and more. Explore Cyprotex's tech stack below.
| Cyprotex Email Formats | Percentage |
| F.Last@cyprotex.com | 94% |
| First.Last@cyprotex.com | 5% |
| FLast@cyprotex.com | 1% |
Research ServicesUnited Kingdom51-200 Employees
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development.
* High-throughput ADME screening
* Customised ADME assays
* In silico ADME predictive modeling
* In vitro toxicology
Company Overview
Funding & FinancialsCyprotex's revenue is estimated to be in the range of $25M$50M
Funding & FinancialsCyprotex's revenue is estimated to be in the range of $25M$50M
1-888-653-2347 
support@leadiq.com